A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Food Effect of Randomized, Double-Blind, Placebo-Controlled Single and Multiple Dose Escalations of CS060304 in Healthy and Elevated LDL-C Subjects
Latest Information Update: 04 Mar 2025
At a glance
- Drugs CS 060304 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Cascade Pharmaceuticals
Most Recent Events
- 26 Feb 2025 Planned initiation date changed from 14 Aug 2024 to 19 Mar 2025.
- 30 Jul 2024 Planned initiation date changed from 14 Jul 2024 to 14 Aug 2024.
- 17 Jul 2024 New trial record